JPMorgan says there's a strong likelihood the FDA is going to approve Amarin's (AMRN) high triglyceride drug AMR101 when it meets on Thursday. Based on the approval, the firm sees a fair price for the shares of around $22 by the end the year. Expect some volatility on the way however, the last time the stock hit those levels was clear back in 2007.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Wed, 8:45AM)
at Zacks.com (Mon, 9:13AM)
at Benzinga.com (Jan 13, 2015)
at CNBC.com (Feb 28, 2014)
at MarketWatch.com (Jan 21, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs